

Cynthia A. Persily, Ph.D.
Cabinet Secretary

Cynthia Beane
Commissioner

Pharmaceutical and Therapeutics Committee

August 28th, 2024

Location: Webex only
Time: Executive Session 2:00 PM - 3:00 PM
Time: Open Session 3:00 PM – 5:00 PM
Charleston, WV 25301
(304) 558-1700

AGENDA

- I. Executive Session- 2:00PM-3:00PM
- II. Call to Order – Call in information for the 3:00 PM Open Session is
+1 952-222-7450 meeting code 558 466 442#
Join on your computer, mobile app or room device
[Join the meeting now](#)
Meeting ID: 227 548 475 595
Passcode: xboPkA
[Download Teams](#) | [Join on the web](#)
- III. Welcome and Introductions
- IV. Housekeeping Items/Updates
 - a. Approval of the January 24th, 2024 Minutes (**April meeting cancelled*)
 - b. PDL Compliance/Generic Percent Report Updates
- V. Public Comments (*Agenda classes only*) – Public comments for this meeting will only be accepted in writing. Comments need to be sent via email to Vicki Cunningham (Vicki.M.Cunningham@wv.gov) no later than August 14th, 2024. Comments will be forwarded to committee members prior to the meeting for their review and consideration.



Representatives of drug manufacturers being presented at P&T can register to be on hand to answer any questions put forth by P&T committee members. Registrants must provide a name, email address, name of drug and company they are representing, and provide a completed [disclosure form](#) to the email address above no later than August 14th, 2024.

VI. New Business

a. New Drug Reviews

- i. Acne Agents, Topical
 1. Cabtreo (clindamycin/adapalene/benzoyl peroxide)
- ii. Anticonvulsants, Benzodiazepines
 1. Libervant buccal film (diazepam)
- iii. Cytokine/CAM Antagonists
 1. Adalimumab-admb
 2. Simlandi (adalimumab-ryvk)
 3. Tofidence (tocilizumab-bavi)
 4. Tyenne (tocilizumab-aazg)
 5. Zymfentra (infliximab-dyyb)
- iv. Diabetes Agents, DPP-4 Inhibitors
 1. Zituvio (sitagliptin)
- v. Dry Eye Products
 1. Vevye (cyclosporine)
- vi. H. Pylori
 1. Voquezna Dual Pak (vonoprazan/amoxicillin)
 2. Voquezna Triple Pak (vonoprazan/amoxicillin/clarithromycin)
- vii. Hyperphosphatemia Agents, Other
 1. Xphozah (tenapanor)
- viii. Opiate Dependence Treatments
 1. Rextovy nasal spray (naloxone)
- ix. PAH Agents, Combinations
 1. Opsynvi (macitentan/tadalafil)
- x. PAH Agents, Actin Signaling Inhibitor
 1. Winrevair (sotatercept-csrk)
- xi. Proton Pump Inhibitors
 1. Voquezna (vonoprazan fumerate)
- xii. VMAT Inhibitors
 1. Austedo XR (deutetrabenazine)
 2. Ingrezza sprinkle caps (valbenazine)

b. Drug Class Reviews

- i. Potassium Removing Agents
 1. SPS (sodium polystyrene sulfonate)
 2. Lokelma (sodium zirconium cyclosilicate)
 3. Veltassa (patiromer calcium sorbitex)



- 4. Kionex (sodium polystyrene sulfonate)
 - ii. Diabetes Agents, SGLT2 Inhibitors
 - 1. Invokana (canagliflozin)
 - 2. Invokamet (canagliflozin/metformin)
- VII. Old Business
- VIII. Other Business
- IX. Next Meeting – October 23rd, 2024 In-Person Meeting 9:00AM – 5:00PM
*Location: Diamond Building, Rooms B10 and B11
350 Capitol Street
Charleston, WV 25301*
- X. Adjournment

